The DOI matches its Crossref record.
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Open accessAbstract
Purpose: Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance. Patients and Methods: Patients included in this study were required to have archived plasma, bone marrow biopsy, and cytogenetic information available at the time of first referral to the Mayo Clinic. Multiplex biometric sandwich immunoassay was used to measure plasma levels of 30 cytokines. Results: In total, 127 PMF patients were studied; comparison with normal controls (n = 35) revealed significantly increased interleukin-1β (IL-1β), IL-1RA, IL-2R, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, tumor necrosis factor α (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon alfa (IFN-α), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, hepatocyte growth factor (HGF), IFN-γ–inducible protein 10 (IP-10), monokine induced by IFN-γ (MIG), monocyte chemotactic protein 1 (MCP-1), and vascular endothelial growth factor (VEGF) levels and decreased IFN-γ levels. In treatment-naive patients (n = 90), increased levels of IL-8 (P < .001), IL-2R (P < .001), IL-12 (P < .001), IL-15 (P = .001), and IP-10 (P = .003) were independently predictive of inferior survival. A similar multivariable analysis that included all 127 study patients confirmed the prognostic value of these five cytokines, and IL-8, IL-2R, IL-12, and IL-15 remained significant when risk stratification, according to the recently revised Dynamic International Prognostic Scoring System (DIPSS plus), was added to the multivariable model. Leukemia-free survival was predicted by IL-8, which was also the only cytokine associated with ≥ 1% circulating blasts. Other cytokine-phenotype associations included increased IL-8 and constitutional symptoms; IL-2R, IL-12, and transfusion need; IL-2R, IL-8, and leukocytosis; IP-10 and thrombocytopenia; HGF, MIG, IL-1RA, and marked splenomegaly; and IL-1RA, IL-2R, IP-10, MIP-1β, and JAK2V617F. A two-cytokine (IL-8/IL-2R) –based risk categorization delineated prognostically different groups within specific DIPSS plus risk categories. Conclusion: This study signifies the presence of specific cytokine-phenotype associations in PMF and a prognostically relevant plasma cytokine signature that might prove useful as a laboratory tool for predicting and monitoring treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“…Dysregulation of bone marrow proinflammatory cytokine production leads to chronically elevated levels of circulating inflammatory cytokines, which drives clonal evolution in MPNs and leads to increased deposition of reticulin and collagencontaining bone marrow stromal fibers (Tefferi et al., 2011).”
BackgroundHasselbalch, H. C. (2012) · Blood · doi:10.1182/blood-2011-11-394775 · Cited by 300
Kleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Barreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Crucian, B. E., Zwart, S. R., Mehta, S., Uchakin, P., Quiriarte, H. D., Pierson, D., Sams, C. F., & Smith, S. M. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0129 · Cited by 195
Wang, L., Zhang, H., Rodriguez, S., Cao, L., Parish, J., Mumaw, C., Zollman, A., Kamoka, M. M., Mu, J., Chen, D. Z., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.021 · Cited by 186
Clonal haematopoiesis and dysregulation of the immune system
Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161
Koschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J.-J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 161
Vaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., & Tefferi, A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23295 · Cited by 149
Self-citationInflammation and myeloproliferative neoplasms
Lussana, F., & Rambaldi, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.010 · Cited by 136
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Pourcelot, E., Trocme, C., Mondet, J., Bailly, S., Toussaint, B., & Mossuz, P. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.006 · Cited by 132
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., et al. (2018) · Blood · doi:10.1182/blood-2018-04-846220 · Cited by 99
Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
Cacemiro, M. D. C., Cominal, J. G., Tognon, R., Nunes, N. D. S., Simões, B. P., Figueiredo-Pontes, L. L. D., Catto, L. F. B., Traina, F., Souto, E. X., Zambuzi, F. A., et al. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2017.12.003 · Cited by 55
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
Schnöder, T. M., Eberhardt, J., Koehler, M., Bierhoff, H. B., Weinert, S., Pandey, A. D., Nimmagadda, S. C., Wolleschak, D., Jöhrens, K., Fischer, T., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2354-1 · Cited by 13
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Gadd45g insufficiency drives the pathogenesis of myeloproliferative neoplasms
Zhang, P., You, N., Ding, Y., Zhu, W., Wang, N., Xie, Y., Huang, W., Ren, Q., Qin, T., Fu, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47297-2 · Cited by 11
Socoro-Yuste, N., Dagher, M.-C., Gonzalez De Peredo, A., Mondet, J., Zaccaria, A., Roux Dalvai, F., Plo, I., Cahn, J. Y., & Mossuz, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.08.012 · Cited by 8
Targeting Immune Signaling Pathways in Clonal Hematopoiesis
Azrakhsh, N. A., Mensah-glanowska, P., Sand, K., & Kittang, A. O. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190325100636 · Cited by 8
Metadata
- Authors
- Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-04-01
- Volume
- 29
- Issue
- 10
- Pages
- 1356-1363
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2111141291
- Cited by
- 608
- References
- 0
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.